Christian Caglevic

9.3k total citations · 2 hit papers
61 papers, 1.9k citations indexed

About

Christian Caglevic is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Christian Caglevic has authored 61 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 43 papers in Oncology, 30 papers in Pulmonary and Respiratory Medicine and 8 papers in Surgery. Recurrent topics in Christian Caglevic's work include Cancer Immunotherapy and Biomarkers (24 papers), Lung Cancer Treatments and Mutations (14 papers) and Gastric Cancer Management and Outcomes (13 papers). Christian Caglevic is often cited by papers focused on Cancer Immunotherapy and Biomarkers (24 papers), Lung Cancer Treatments and Mutations (14 papers) and Gastric Cancer Management and Outcomes (13 papers). Christian Caglevic collaborates with scholars based in Chile, United States and Italy. Christian Caglevic's co-authors include Christian Rolfo, Matteo S. Carlino, Caroline Robert, Georgina V. Long, Stéphane Dalle, Scott J. Diede, James Larkin, Lev Demidov, Jean‐Jacques Grob and Reinhard Dummer and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer Research.

In The Last Decade

Christian Caglevic

57 papers receiving 1.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study

2019 703 citations Georgina V. Long, Reinhard Dummer et al. The Lancet Oncology profile →
Five-Year Outcomes With Pembrolizumab Versus Chemotherapy as First-Line Therapy in Patients With Non–Small-Cell Lung Cancer and Programmed Death Ligand-1 Tumor Proportion Score ≥ 1% in the KEYNOTE-042 Study

2022 151 citations Gilberto de Castro, Iveta Kudaba et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Christian Caglevic

Since Specialization

Citations

This map shows the geographic impact of Christian Caglevic's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christian Caglevic with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christian Caglevic more than expected).

Fields of papers citing papers by Christian Caglevic

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christian Caglevic. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christian Caglevic. The network helps show where Christian Caglevic may publish in the future.

Co-authorship network of co-authors of Christian Caglevic

This figure shows the co-authorship network connecting the top 25 collaborators of Christian Caglevic. A scholar is included among the top collaborators of Christian Caglevic based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christian Caglevic. Christian Caglevic is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	2792TiP A phase Ib/II study of gocatamig (MK-6070; HPN328) and ifinatamab deruxtecan for relapsed/refractory extensive-stage small cell lung cancer (ES-SCLC) 2025 ·Annals of Oncology ·Jair Bar, (unknown), (unknown), (unknown), (unknown), Christian Caglevic, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Ryo Ariyasu, (unknown), (unknown), Vassiliki Karantza, (unknown), Ann W. Gramza, (unknown)	0
2	Distribución geográfica de la incidencia de cáncer de beneficiarios de un convenio de atención oncológica en Chile 2023 ·Revista médica de Chile ·(unknown), (unknown), (unknown), Gabriel Cavada, (unknown), (unknown), Christian Caglevic, J Sapunar	1
3	Five-Year Outcomes With Pembrolizumab Versus Chemotherapy as First-Line Therapy in Patients With Non–Small-Cell Lung Cancer and Programmed Death Ligand-1 Tumor Proportion Score ≥ 1% in the KEYNOTE-042 Study breakdown → 2022 ·Journal of Clinical Oncology ·Gilberto de Castro, Iveta Kudaba, Yi‐Long Wu, Gilberto Lopes, Dariusz M. Kowalski, H.Z. Turna, Christian Caglevic, Li Zhang, Bogusława Karaszewska, К. К. Лактионов, Vichien Srimuninnimit, Igor Bondarenko, (unknown), (unknown), Jianxin Lin, Fabricio Souza, Tony Mok, Byoung Chul Cho	151
4	Takotsubo cardiomyopathy Afatinib-related in a non-small cell lung cancer patient: Case report 2022 ·Frontiers in Cardiovascular Medicine ·(unknown), Christian Caglevic, (unknown), (unknown), (unknown), (unknown), (unknown)	5
5	Molecular determinants of clinical outcomes with pembrolizumab versus paclitaxel in a randomized, open-label, phase III trial in patients with gastroesophageal adenocarcinoma 2021 ·Annals of Oncology ·Kohei Shitara, Mustafa Özgüroğlu, (unknown), Maria Di Bartolomeo, Mario Mandalà, (unknown), Christian Caglevic, Hyun Cheol Chung, Kei Muro, Eric Van Cutsem, Julie Kobie, Răzvan Cristescu, Deepti Aurora-Garg, Lu Jia, (unknown), David E. Adelberg, Z. Alexander Cao, Charles S. Fuchs	42
6	Clinical characterization and treatment of head and neck mucosal melanoma: a Chilean experience 2021 ·Oral Surgery Oral Medicine Oral Pathology and Oral Radiology ·(unknown), Manuel Meneses, (unknown), Christian Caglevic, (unknown), (unknown), (unknown), (unknown)	2
7	Pembrolizumab versus paclitaxel for previously treated PD-L1-positive advanced gastric or gastroesophageal junction cancer: 2-year update of the randomized phase 3 KEYNOTE-061 trial 2021 ·Gastric Cancer ·Charles S. Fuchs, Mustafa Özgüroğlu, Yung‐Jue Bang, Maria Di Bartolomeo, Mario Mandalà, Min‐Hee Ryu, Lorenzo Fornaro, Tomasz Olesiński, Christian Caglevic, Hyun Cheol Chung, Kei Muro, Eric Van Cutsem, Anneli Elme, Peter Thuss‐Patience, Ian Chau, Atsushi Ohtsu, Pooja Bhagia, Anran Wang, Chie‐Schin Shih, Kohei Shitara	112
8	1459P Albumin as a simple criterion to reduce early mortality (EM) in gastric cancer (GC) trials 2020 ·Annals of Oncology ·Mustafa Özgüroğlu, Kohei Shitara, Kyung-Woo Lee, Charles S. Fuchs, Hyun Cheol Chung, Maria Di Bartolomeo, Joseph Chao, Zev A. Wainberg, Christian Caglevic, Iveta Kudaba, (unknown), Marcelo Garrido, (unknown), Jiemin Ma, Z. Alexander Cao, Sukrut Shah, (unknown), Pooja Bhagia, Lucjan Wyrwicz, Josep Tabernero	1
9	Potential use of n-3 PUFAs to prevent oxidative stress-derived ototoxicity caused by platinum-based chemotherapy 2020 ·Free Radical Biology and Medicine ·(unknown), Mauricio Burotto, Mauricio A. Retamal, (unknown), Christian Caglevic, Juan G. Gormaz	4
10	Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study breakdown → 2019 ·The Lancet Oncology ·Georgina V. Long, Reinhard Dummer, Omid Hamid, Thomas F. Gajewski, Christian Caglevic, Stéphane Dalle, Ana Arance, Matteo S. Carlino, Jean‐Jacques Grob, Tae Min Kim, Lev Demidov, Caroline Robert, James Larkin, James R. Anderson, Janet Maleski, Mark M. Jones, Scott J. Diede, Tara C. Mitchell	703
11	Oncogenic role of arsenic exposure in lung cancer: A forgotten risk factor 2019 ·Critical Reviews in Oncology/Hematology ·Cristian Soza‐Ried, Eva Bustamante, Christian Caglevic, Christian Rolfo, Rafael Sirera, (unknown)	45
12	Vaccine and immune cell therapy in non-small cell lung cancer 2018 ·Journal of Thoracic Disease ·(unknown), Christian Caglevic, Francesco Passiglia, Simona Taverna, Evelien Smits, Christian Rolfo	33
13	KEYNOTE-033: Phase 3 study of pembrolizumab versus docetaxel in patients with previously treated non–small-cell lung cancer (NSCLC) 2017 ·Annals of Oncology ·C.Z. Zhou, Christian Caglevic, Jianying Zhou, (unknown), (unknown), Joy Yang Ge, (unknown), Bilal Piperdi, Z. Ma	3
14	Immune checkpoint inhibitors in lung cancer: the holy grail has not yet been found… 2017 ·ESMO Open ·Satheesh Chiradoni Thungappa, (unknown), Christian Caglevic, Francesco Passiglia, Luis E. Raez, Christian Rolfo	16
15	Immunotherapy in NSCLC: A Promising and Revolutionary Weapon 2017 ·Advances in experimental medicine and biology ·Christian Rolfo, Christian Caglevic, Mariacarmela Santarpía, António Araújo, Elisa Giovannetti, (unknown), Patrick Pauwels, Mauricio Mahave	104
16	Second-Line Treatment of Non-Small Cell Lung Cancer: Clinical, Pathological, and Molecular Aspects of Nintedanib 2017 ·Frontiers in Medicine ·Luis Corrales, Amanda Nogueira, Francesco Passiglia, Angela Listì, Christian Caglevic, Marco Giallombardo, Luis E. Raez, Edgardo S. Santos, Christian Rolfo	16
17	BRAF mutations in non-small cell lung cancer: has finally Janus opened the door? 2016 ·Critical Reviews in Oncology/Hematology ·Rafael Caparica, Gilberto de Castro, Ignacio Gil‐Bazo, Christian Caglevic, Raffaele Calogero, Marco Giallombardo, Edgardo S. Santos, Luis E. Raez, Christian Rolfo	14
18	The potential of neurotrophic tyrosine kinase (NTRK) inhibitors for treating lung cancer 2016 ·Expert Opinion on Investigational Drugs ·Francesco Passiglia, Rafael Caparica, Elisa Giovannetti, Marco Giallombardo, Angela Listì, Patrizia Diana, Girolamo Cirrincione, Christian Caglevic, Luis E. Raez, Antonio Russo, Christian Rolfo	23
19	Mesenchymal stem cell therapy for doxorubicin cardiomyopathy: hopes and fears 2015 ·Stem Cell Research & Therapy ·Fernando Ezquer, Jaime Gutiérrez, Marcelo Ezquer, Christian Caglevic, Hélio César Salgado, Sebastián D. Calligaris	21
20	Report from the First Latin American Urological Oncology Symposium (SLAURO) 19–21 June 2014, Viña del Mar, Chile 2014 ·ecancermedicalscience ·Christian Caglevic	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact